Magrath I, Jain V, Bhatia K
Lymphoma Biology Section, Pediatric Branch, National Cancer Institute, Bethesda, MD.
Semin Cancer Biol. 1992 Oct;3(5):285-95.
Recent investigations indicate that Burkitt's lymphoma consists of several subtypes, defined by their clinical and molecular features. Each geographical region so far studied appears to consist of a different mixture of subtypes. Interestingly, there appear to be geographic 'gradients' with respect to the fraction of tumors associated with EBV and the type of 8;14 chromosomal translocation. The rate of EBV association is highest in Equatorial Africa, lowest in North America and intermediate in South America. The fraction of tumors with breakpoints far upstream of the c-myc gene follows a similar pattern. These findings strongly suggest that the subtypes of Burkitt's lymphoma are environmentally determined, and we propose that the pattern of infection (e.g. malaria) to which the young child is exposed influences the tumor subtype distribution by altering the relative and absolute numbers of various B cell precursors at sites of B cell ontogeny (the bone marrow, and possibly mesentery). These B cell precursors are the cells which are susceptible to the specific chromosomal translocations associated with Burkitt's lymphoma. We further propose that immunoglobulin enhancers (recognized and unrecognized) both influence the likelihood of the translocation occurring, and in at least a fraction of cases, contribute to the deregulation of a c-myc. EBV, via EBNA-1, the only invariably expressed latent-gene in Burkitt's lymphoma, probably influences c-myc expression in Burkitt's lymphoma by increasing immunoglobulin enhancer function. Thus, in effect, EBV collaborates with the translocations associated with Burkitt's lymphoma in causing c-myc deregulation. This collaboration is independent of the breakpoint location. While other molecular abnormalities must be able to contribute to myc deregulation in the same way, EBV association in Burkitt's lymphoma is probably determined by the age at which EBV infection occurs (being more likely when infection occurs in very young children) and perhaps also by other infectious diseases that numerically influence the fraction, and predominant stage of differentiation (and hence translocation breakpoint sites) of immature B cells infected by EBV. The presence of EBV in many such cells greatly increases the incidence rate of Burkitt's lymphoma, since one of the genetic lesions needed to deregulate c-myc is already present.
近期研究表明,伯基特淋巴瘤由几种亚型组成,这些亚型由其临床和分子特征所定义。到目前为止,每个已研究的地理区域似乎都由不同的亚型混合组成。有趣的是,在与EBV相关的肿瘤比例以及8;14染色体易位类型方面,似乎存在地理“梯度”。EBV关联率在赤道非洲最高,在北美最低,在南美居中。具有c-myc基因上游远处断点的肿瘤比例也呈现类似模式。这些发现强烈表明,伯基特淋巴瘤的亚型是由环境决定的,我们提出幼儿接触的感染模式(如疟疾)通过改变B细胞发生部位(骨髓,可能还有肠系膜)各种B细胞前体的相对和绝对数量,影响肿瘤亚型分布。这些B细胞前体是易受与伯基特淋巴瘤相关的特定染色体易位影响的细胞。我们进一步提出,免疫球蛋白增强子(已识别和未识别的)既影响易位发生的可能性,并且在至少一部分病例中,促成c-myc的失调。EBV通过EBNA-1(伯基特淋巴瘤中唯一始终表达的潜伏基因),可能通过增强免疫球蛋白增强子功能来影响伯基特淋巴瘤中的c-myc表达。因此,实际上,EBV与伯基特淋巴瘤相关的易位协同作用导致c-myc失调。这种协同作用与断点位置无关。虽然其他分子异常肯定也能够以同样的方式促成myc失调,但伯基特淋巴瘤中EBV的关联可能取决于EBV感染发生的年龄(在幼儿期感染时更有可能),也许还取决于其他传染病,这些传染病在数量上影响被EBV感染的未成熟B细胞的比例以及分化的主要阶段(从而影响易位断点位置)。许多此类细胞中EBV的存在大大增加了伯基特淋巴瘤的发病率,因为使c-myc失调所需的一种基因损伤已经存在。